

COVID-19 Therapeutics Strategy

THURSDAY 6 MAY 2021

Vaccination rates are increasing across the EU, but therapeutics or treatments are vital to treat those people who are still falling ill and reduce the rate of **acute** and **severe COVID**.



TO DATE:

1

Number of authorised COVID-19 therapeutics

3

Number of therapeutics under rolling review (pre-authorisation)

57

Number of potential therapeutics the European Medicines Agency has advised on

70

Number of joint procurement contracts for medicines

WITH THE THERAPEUTICS STRATEGY:

3-5

Newly authorised medicines in 2021

3

New joint procurements of therapeutics

7

New rolling reviews

THE STRATEGY PROMOTES AN END-TO-END APPROACH TO COVID-19 THERAPEUTICS:

RESEARCH, DEVELOPMENT AND INNOVATION

Set up a **'therapeutics innovation booster'** to develop a clear overview of therapeutics projects under development in order to better support the most promising ones from preclinical research to market authorisation.



ACCESS AND SWIFT APPROVAL OF CLINICAL TRIALS

Facilitate authorisations at national level to encourage large, multi-country clinical trials.

Invest **€5 million** in **clinical trials safety assessments** and improving safety data.

Provide financial support of **€2 million** for **expedited and coordinated assessments** to facilitate approval of clinical trials.

Invest in producing **high-grade material for clinical trials**.



SCANNING FOR CANDIDATE THERAPEUTICS

Invest **€5 million** to **map treatments** in their development stage, production capacities and supply chains.

Draw up a **list of 10 potential therapeutics** including the 5 most promising ones by June.



SUPPLY CHAINS AND DELIVERY OF MEDICINES

Fund a **€40 million preparatory action** to support flexible manufacturing and access for COVID-19 therapeutics under the EU Fab project.


HERA Incubator will help manufacturers and other industrial players team up to produce therapeutics via a dedicated matchmaking event.



REGULATORY FLEXIBILITY

Authorise **3 additional therapeutics** and start **7 rolling reviews** by end-2021.

Health data pilot project to give EU medical regulators quicker access to safety and efficacy data.



JOINT PROCUREMENT AND FINANCING

Conclude **3 new joint procurement contracts** for authorised COVID-19 medicines by end-2021.

Explore the use of **advance purchase agreement** to boost the development and production of therapeutics.

Streamline solutions to secure faster access to medicines with:

- shorter administrative deadlines
- an allocation mechanism for scarce products
- minimum orders in the first few months
- no parallel national procurement for the same products or services.

INTERNATIONAL COOPERATION

Fair distribution of therapeutics, notably through the **Access to COVID-19 Tools Accelerator**

